Ladies and gentlemen, I am pleased to report that BTC Health Limited (ASX:BTC) has achieved a number of milestones over the past 12 months, including a greater penetration of our products within hospitals.
I am pleased to provide you with a detailed update on BTC Health Limited's (ASX:BTC) investments, along with an operational update of BTC's wholly owned investee companies.
The primary objective for BTC Speciality Health is to increase market share through organic growth. New products will continue to be sourced by BioImpact and will enable BTC Speciality Health to expand its product range within pain management and critical care.
Medlab Clinical Ltd (ASX:MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement with WEP Clinical Ltd for the exclusive development and delivery of Named Patient Programmes
BTC Health Limited (ASX:BTC) is pleased to announce its investee company, BioImpact Pty Ltd, has acquired exclusive distribution rights for specialty respiratory brands Bronchitol(R) and Aridol(R) from Pharmaxis (ASX:PXS) in Australia, New Zealand, Singapore, Malaysia, Hong Kong and South Korea (Bronchitol(R) only).
BTC Health Limited (ASX:BTC) is pleased to announce the receipt of binding firm commitments for a $2.5 million private placement to fund the acquisition of exclusive distribution rights to Bronchitol(R) and Aridol(R) in Australia, New Zealand, Malaysia, Hong Kong and Singapore.
Diagnos Inc. (CVE:ADK) (OTCMKTS:DGNOF) (4D4A.F), a leader in early detection of critical health issues, is pleased to announce the signing of a multi-year agreement with IRIS The Visual Group (1990) Inc.
Diagnos Inc. (CVE:ADK) (OTCMKTS:DGNOF) (FRA:4D4A), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of an exclusive distribution agreement with Diagnos Europe GmbH.
Cortical is an Australian based medical device technology company that has developed an industry disruptive brain function monitor independently described as "a paradigm busting technology from an Australian based device house that really gives a significant advantage in this space".
Cann Global continued to drive sales throughout the quarter resulting in cash receipts from customers of $333k up 54.6% on the prior corresponding period, but lower than the prior quarter due to shipping delays and therefore delayed payment on contracted sales.
